|Awarded On||February 18, 2015|
|Title||T-cell activating immunotherapy for indolent B-cell malignancies|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Sattva Neelapu|
Chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL) are the most common slow-growing B-cell lymphomas worldwide that are currently incurable. The observation of long-term remissions with allogeneic stem cell transplantation or genetically modified T-cell therapy suggested that agents that activate T cells against the tumor could be highly effective therapies for these patients. In the current proposal, we will test three novel strategies to activate T cells. These approaches will be evaluated in a mouse model that mimics human CLL. Therefore, following completion of this project, we expect to translate our findings for testing in patients with CLL, FL, and other B-cell lymphomas....